HIV/AIDS News

DENVER — Long-acting injectable ART administered every 8 weeks safely suppresses HIV in adolescents, according to research presented at the Conference on Retroviruses and Opportunistic Infections.

DENVER — Giving patients the option of choosing long-acting PrEP resulted in a fivefold increase in coverage and a reduction in HIV incidence during the SEARCH trial in Uganda, researchers reported.

DENVER — Phase 2 study data showed that a once-weekly oral regimen of an investigational two-drug HIV treatment was well tolerated among patients with HIV and allowed them to maintain viral suppression.

DENVER — The International Antiviral Society-USA (IAS-USA) has updated its HIV treatment guidelines to endorse the off-label use of long-acting injectable ART in patients with HIV viremia.

DENVER — New data from a cohort of adolescent and young women in sub-Saharan Africa showed a higher level of HIV PrEP adherence than has been reported in previous studies, researchers said.

DENVER — A new study provides reassurances that PrEP can reliably prevent HIV in cisgender women, even if they do not use it daily.

DENVER — Data from the United States and Australia show that PrEP uptake and adherence has increased, and the incidence of HIV has declined in recent years, researchers reported.

DENVER — A cocktail composed of three broadly neutralizing monoclonal antibodies resulted in long-term virologic control in people with HIV after they discontinued ART, researchers found.

When I was in high school, I was given the opportunity to take a part-time job that was a little out of the ordinary for my age: I worked for a clinical microbiologist selling sterile sheep blood to microbiology laboratories to make bacterial culture agar.

As it does every year, the Conference on Retroviruses and Opportunistic Infections is shining a spotlight on emerging research in HIV over the course of 4 days, this year at the Colorado Convention Center in Denver.